Synthetic clinical data reality check—not so fast, data replacers
In Part 1 of this blog post, we mapped healthcare’s market for clinical data—a.k.a “Real World Data” or RWD. We looked at a bunch of the key components, including: The different types of clinical data, including who owns usable data (providers, payers, EHR vendors, multi-source aggregators).
At a glance
Read on to get our full commentary, or use the links below to jump to a specific area of interest:
-
Quick rewind: Our tour of the clinical data market that…
-
A guided tour of the synthetic clinical data market (2025)
-
Why synthetic clinical data adoption isn’t a slam-dunk
- #1: You can’t make synthetic clinical data sets without first…
- #2: You can’t validate synthetic clinical data without investing in…
- #3: Synthetic data’s regulatory burden is lighter—but definitely not zero
- #4: Uncertainty makes the synthetic clinical data regulatory burden heavier
- #5: Standards wild west: No single source of truth in…
- #6: Clinician skepticism will slow uptake in some use cases
- #1: You can’t make synthetic clinical data sets without first…
-
So…what’s the bottom line here? Will synthetic clinical data ruin…
-
In summary…
Quick rewind: Our tour of the clinical data market that ended in a cliffhanger
In Part 1 of this blog post (linked below if you missed it!), we mapped healthcare’s market for clinical data—a.k.a “Real World Data” or RWD. We looked at a bunch of the key components, including: The different types of clinical data, including who owns usable data (providers, payers, EHR vendors, multi-source aggregators). Why health systems have found what seems like a proprietary “data goldmine” to be so hard to monetize. And, how third-party aggregators have stitched together nationwide, longitudinal data sets that life-science, tech and payer buyers are willing to pay for. And THEN came the cliffhanger: in theory, AI can now generate statistically identical, privacy-risk-free “synthetic” data sets. Essentially, generated data that has all the characteristics of RWD, but isn’t RWD. On paper, synthetic clinical data seems to solve a lot of the pain points associated with the real thing—HIPAA worries, consent barriers, data breach headlines, six-figure license fees—so…is the market for actual clinical data about to be ruined? Today we tackle that question head-on.
Missed part 1 on the “Real World Data” market? Catch up by clicking here.
Union Healthcare Insight
Log in to continue reading
Not a member yet? Create a free account for limited access.
Related insights
Healthcare’s next forced efficiency leap is AI. Where does your organization stand?
The health-system utilization forecasting conundrum: One size definitely doesn’t fit all.
Key takeaways from our Chicago Revenue Cycle Summit